Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

OBJECTIVE: To evaluate the cardiovascular and renal benefits of finerenone, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients with Type 2 Diabetes Mellitus (T2DM) and chronic kidney disease (CKD) with network meta-analysis. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yaofu, Jiang, Li, Wang, Junheng, Wang, Tongxin, Chien, Chieh, Huang, Weijun, Fu, Xiaozhe, Xiao, Yonghua, Fu, Qiang, Wang, Shidong, Zhao, Jinxi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637313/
https://www.ncbi.nlm.nih.gov/pubmed/36335326
http://dx.doi.org/10.1186/s12933-022-01676-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637313/
https://www.ncbi.nlm.nih.gov/pubmed/36335326
http://dx.doi.org/10.1186/s12933-022-01676-5

Ejemplares similares